Advertisement
Advertisement
STOK
Stoke Therapeutics, Inc. Common Stock
26.54
USDSponsored
+0.47
+1.80%
Nov 06, 15:59 UTC -5
Closed
After-Market
27.13
+0.59
+2.22%
Stoke Therapeutics, Inc. Common Stock (STOK) Earnings
STOK Earnings Reports
Positive Surprise Ratio
STOK beat 18 of 30 last estimates.
60%
Next Report
Date of Next Report
Mar 15, 2027
Estimate for Q4 26 (Revenue/ EPS)
$7.53M
/-$1.12
Implied change from Q3 26 (Revenue/ EPS)
-33.09%
/+3.70%
Implied change from Q4 25 (Revenue/ EPS)
+437.11%
/+15.46%
Stoke Therapeutics, Inc. Common Stock earnings per share and revenue
On Oct 29, 2026, STOK reported earnings of -1.08 USD per share (EPS) for Q3 26, missing the estimate of -0.94 USD, resulting in a -14.03% surprise. Revenue reached 11.26 million, compared to an expected 8.35 million, with a 34.82% difference. The market reacted with a -0.23% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -1.12 USD, with revenue projected to reach 7.53 million USD, implying an increase of 3.70% EPS, and decrease of -33.09% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Stoke Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Stoke Therapeutics, Inc. Common Stock reported EPS of -$1.08, missing estimates by -14.03%, and revenue of $11.26M, 34.82% above expectations.
How did the market react to Stoke Therapeutics, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -0.23%, changed from $26.35 before the earnings release to $26.29 the day after.
When is Stoke Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 15, 2027.
What are the forecasts for Stoke Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Stoke Therapeutics, Inc. Common Stock is expected to report EPS of -$1.12 and revenue of $7.53M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.